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• HPV distribution was markedly polarised by age in women referred to colposcopy.
• HPV16/18 was twice as common in women b30 years than in women ≥45 with HSIL lesions.
• In women ≥45 years other high-risk HPVs were more common in HSIL lesions.
• In women ≥45 years approximately 10% of HSIL lesions were negative for high-risk HPV.⁎ Corresponding author.
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Available online 5 June 2019Background and aim. Age-speciﬁc type-distribution of high-risk human papillomavirus (hrHPV) in cervical
precancerous lesions is subject to change in the HPV vaccination era. Knowing the pre-vaccination type-
distribution helps to anticipate changes induced by mass vaccination and optimize screening.
Methods.We recruited 1279 women referred to colposcopy for abnormal cytology into a population-based
study on HPV type distribution in diagnostic cervical samples (ISRCTN10933736). The HPV genotyping ﬁndings
were grouped as: HPV16/18+, other hrHPV+ (HPV31/33/35/39/45/51/52/56/58/59/66/68), non-vaccine
targeted hrHPV+ (HPV35/39/51/56/59/66/68), low-risk HPV, and HPV negative. We estimated the HPV
group-speciﬁc prevalence rates according to diagnostic histopathological ﬁndings in the age groups of b30 (n
= 339), 30–44.9 (n = 614), and ≥45 (n = 326).
Results. Altogether 503 cases with high grade squamous intraepithelial lesion or worse (HSIL+) were diag-
nosed. More than half, 285 (56.7%) of HSIL+ cases were associated with HPV16/18: 64.3% (101/157) in
women b30 years (reference group), 58.4% (157/269) in women 30–44.9 years (risk ratio (RR) 0.91, 95% conﬁ-
dence interval (95% CI) 0.78–1.06), and 35.1% (27/77) in women ≥45 years of age (RR 0.55, 95% CI 0.39–0.75).
Conversely, other hrHPV's were associated with 191 (38.0%) of HSIL+: 31.9% (50/157) in women b30, 36.8%
(99/269) inwomen 30–44.9 years, 54.6% (42/77) and inwomen ≥45 (RR 1.71, 95% CI 1.26–2.33). The proportion
of non-vaccine targeted hrHPV and HPV negative HSIL+ increased with advancing age.
Conclusions. Pre-vaccination HPV type distribution in HSIL+ was distinctly polarised by age with HPV16/18
attributed disease being markedly more prevalent in women aged b30. In the older women the other hrHPV
types, however, dominated suggesting a need for more age-dependent screening strategies.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The prevalence of high-risk human papillomavirus (hrHPV) peaks in
youngwomen, with HPV16 being globally themost common type [1,2].
Approximately 70% of cervical cancers are associated with HPV16 and
HPV18, the types targeted by all three prophylactic vaccines [3–6]. The
latest 9-valent vaccine directly also targets ﬁve other hrHPVs (HPV31/
33/45/52/58), and the bivalent vaccine is reported to have moderate
to high cross-protective efﬁcacy against a number of other hrHPV
types (HPV31/33/35/45/52) [7–11]. Prophylactic HPV vaccines havethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(HSIL), especially in young HPV naïve women [12,13]. Evidence on
protection against invasive cervical cancer from a randomised set-
ting has been reported but long-term efﬁcacy is yet to be conﬁrmed
[14]. Comprehensive data of a dramatic decrease in hrHPV infections
and HSIL approximately a decade after vaccination are very promis-
ing [15–22].
Histological HSIL is most prevalent in women in their late
twenties or early thirties [23]. The peak incidence of cervical cancer
in well-screened populations is among 30–40-year-olds, but re-
mains elevated with advancing age when cervical cancer mortality
also increases [24]. An age-speciﬁc pattern of hrHPV type distribu-
tion with larger proportions of cervical cancer in older women at-
tributed to other hrHPV types than HPV16/18 has been observed,
but type distribution in HSIL has conﬂicting results [25–29]. At the
same time with the initiation of HPV vaccination programs a shift
from cytological screening to hrHPV-based screening has taken
place [30–32], and HPV16/18 genotyping has been advocated as a
triage test on the urgency of colposcopy after a positive hrHPV test
regardless of age [33].
Our objective was to study the current age-speciﬁc hrHPV type dis-
tribution in cervical HSIL lesions in unvaccinated highly screened
women. These data are essential in optimizing current and future
screening programs.2. Material and methods
Women 18 years of age or older referred to Helsinki University Hos-
pital Colposcopy Unit for abnormal cytology between January 2014 and
May 2016 were recruited to participate in a prospective cohort study
(HELICOPTER study: ISRCTN10933736). The unit is the single referral
center in the Helsinki metropolitan area with 4500 annual colposcopies
serving a population base of over onemillion. For this study, we only in-
cluded women with abnormal cytology without symptoms or clinical
pathologicalﬁndings as the reason of referral. Clinical datawas collected
at the ﬁrst colposcopy, and if large loop excision of the transformation
zone (LLETZ) was performed based on punch biopsy results, data on
that visit was collected as well. All women were examined and treated
according to Finnish Current Care guidelines [34]. The protocol was ap-
proved byHelsinki University Hospital's Ethical Committee (130/13/03/
03/2013, 24.4.2013), and written informed consent was acquired from
all participants.2.1. Screening and colposcopy
During the study period organised screeningwas conducted by con-
ventional cervical cytology at ﬁve-year intervals. The age of onset and
ﬁnish of screening varied between municipalities, from 25–30 up to
60–65 years. Opportunistic screening outside the nationwide program
was also mainly conducted by conventional cytology. After referral for
abnormal cytology colposcopy was performed within time frames set
by Finnish Current Care guidelines (Table A.1) [34].
A senior colposcopist with national certiﬁcation or N100 annual
colposcopies was always present at colposcopy. In addition to routine
samples, endocervical cells were obtained with a brush for HPV
genotyping. Decision to treat was mostly based on colposcopically di-
rected punch biopsies. The threshold for treatment was histopathologi-
cally conﬁrmed cervical intraepithelial neoplasia grade 2 orworse (CIN2
+). Themethod of treatment for preinvasive disease was always LLETZ,
performedusuallywithin onemonth of the initial visit.Women referred
for cytological HSIL with inadequate colposcopy or suspicion of high-
grade lesion at colposcopy were treated with LLETZ at ﬁrst colposcopy.
LLETZ was performed at ﬁrst visit also for atypical glandular cells,
favor neoplasia (AGC-FN).2.2. Clinical data
Clinical data was obtained from the electronic hospital records in-
cluding a dedicated colposcopy database and histo- and cytopathology
reports. Cytologywas reported according to the Bethesda system.Histo-
pathological diagnosis was regarded as negative for intraepithelial le-
sion or malignancy (NILM) when no abnormalities with evidence of
HPV were detected. Histopathological low-grade squamous
intraepithelial lesion (LSIL) was deﬁned as either HPV atypia/atypia
condylomatosa or cervical intraepithelial neoplasia grade 1 (CIN1). His-
topathological HSIL was stratiﬁed between cervical intraepithelial neo-
plasia grades 2 and 3 (CIN2 and CIN3). Preinvasive glandular dysplasia
was reported as adenocarcinoma in situ (AIS). The most severe histo-
pathological diagnosis from punch biopsies or LLETZ specimen was in-
cluded in the analysis. The colposcopists, cytologists, and
histopathologists were unaware of the HPV genotyping results.
2.3. HPV genotyping
The endocervical cells in Sample Transport Medium (STM, Qiagen
GMBH, Hilden, Germany) were stored at −20 °C and later divided
into three aliquots without adding any medium and then stored at
−80 °C. One aliquot from each sample was sent frozen to Karolinska In-
stitute, Stockholm, Sweden, for genotyping which was performed with
the Luminex assay as previously described [35].
2.4. Statistical analyses
Themain outcomemeasureswere the age-group speciﬁc prevalence
of HPV types and their association with cervical histopathological diag-
nosis. For all analyses the women were divided into three age-strata:
b30, 30–44.9, and ≥45 years of age.We grouped theHPV data as follows:
HPV16/18+, other hrHPV+ (HPV31/33/35/39/45/51/52/56/58/59/66/
68), hrHPV not directly targeted by prophylactic HPV vaccines (non-
vaccine hrHPV+: HPV35/39/51/56/59/66/68), other HPV than high-
risk (only low-risk HPV: HPV6/11/30/40/42/43/53/61/67/69/70/73/74/
81/83/86/87/89/90/91), and HPV negative. When multiple HPV types
were detected, a hierarchical model was used. Other hrHPV and non-
vaccine hrHPV were considered positive only if HPV16 and/or HPV 18
were not present, and only low-risk HPV was positive only if hrHPVs
(HPV16/18/31/33/35/39/45/51/52/56/58/59/66/68) were not present.
The individual HPV groups were positive if any or multiple of the in-
cluded types in the individual groups were present.
For analyses, we grouped histopathological CIN3 and squamous cell
carcinoma together as CIN3+, and AIS and invasive adenocarcinoma as
AIS+. All high grade cervical histopathological ﬁndings were combined
as HSIL+ (including CIN2, CIN3, AIS, squamous cell carcinoma and ade-
nocarcinoma). NILM and LSIL were combined as less than HSIL (bHSIL).
We calculated the proportions of different HPV types and HPV
groups according to age and histopathological category. We estimated
the risk ratios (RR) of being HPV group positive between different age
groups according to histopathological ﬁndings using binomial logistic
regression with the women b30 years of age set as the referent group.
All statistical analyses were done with STATA 15 (STATA Corp., College
Station, TX).
3. Results
The study comprised of 1302 women (mean age 37.5) referred for
cytological abnormality and HPV typing results were available in 1279
women (Table 1). For six cases (0.5%) the DNA sample was not taken,
and in 17 (1.3%) cases the DNA extraction failed. Of the 23 cases with
no HPV typing data available, 16 had histopathological NILM or LSIL,
four had CIN2, two had CIN3, and one had invasive cervical cancer (ad-
enocarcinoma). Of the 1279 women 1058 (82.7%) were HPV positive
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Caucasian ancestry and only two were HIV positive.
The most prevalent HPV type was HPV16, found in 362 cases
(28.3%). The prevalence of HPV16 decreased with increasing age
(Table 2). Conversely, the proportion of HPV negative cases increased
with age, being 32.2% (105/326) in women over 45. Multiple HPV
types were found in 340 women (26.6%) and were most common in
women b30 years of age. The proportion of HPV16/18 decreased with
advancing age irrespective of histopathological ﬁndings (Table 2).
Cervical histopathology results were available for 1261 (98.6%)
women (Table 1). The remaining women (n = 18) had normal colpos-
copy of the cervix and histopathological sampling was not performed.
Histopathological HSIL+ was found in 503 (39.3%) cases and low-
grade or normal histopathological ﬁndings (bHSIL) in 776 (60.7%) cases.
3.1. Association of HPV types with high-grade histology
HPV16/18 positivity increased with increasing severity of histopath-
ological ﬁndings, whereas HPV negativity decreased with advancing
histopathological grade of squamous lesions (Fig. 1). The oldest age-
group had the greatest proportions of disease attributed to other
hrHPV types than HPV16/18 or HPV negative lesions.
In total 285 of the 503 cases of HSIL+ (56.7%) were associated with
HPV16/18,withHPV16 being themost common genotype found inHSIL
+ in all age-groups (Table 3, Fig. 1, Table A.2). Other hrHPV types
(HPV31/33/35/39/45/51/52/56/58/59/66/68) accounted for 191/503
(38.0%) cases of HSIL+ and non-vaccine targeted hrHPV types
(HPV35/39/51/56/59/66/68) for 35/503 (7.0%). In women b30 years
64.3% (101/157) of the HSIL+ cases were associated with HPV16/18.
The corresponding ﬁgures were 58.4% (157/269, RR 0.91, 95% conﬁ-
dence interval (95% CI) 0.78–1.06) in women 30–44.9 years, and
35.1% (27/77, RR 0.55, 95% CI 0.39–0.75) in women ≥45 years. Other
hrHPV types than HPV16/18 on the other hand covered 31.9% (50/Table 1
Characteristics of 1279 women referred to colposcopy for abnormal cytology with HPV
typing results by age strata.
All
n = 1279
b30
n = 339
30–44.9
n = 614
≥45
n = 326
Age median (range) 35.1
(19.2–83.7)
26.1
(19.2–29.9)
35.2
(30.0–44.9)
51.4
(45.0–83.7)
Referral reason % n % n % n % n
ASC-US (repeated) 10.6 135 14.5 49 6.0 37 15.0 49
LSIL 39.3 502 26.6 90 44.6 274 42.3 138
ASC-H 24.9 318 31.6 107 23.6 145 20.3 66
HSIL 19.8 253 25.1 85 21.2 130 11.7 38
AGC-NOS 3.4 43 1.5 5 2.6 16 6.8 22
AGC-FN 2.2 28 0.9 3 2.0 12 4.0 13
Repeated abnormal
cytologya
28.9 370 41.0 139 23.3 143 27.0 88
Baseline cervical histology
NILM 30.0 383 20.9 71 24.6 151 49.4 161
LSIL 29.3 375 31.3 106 30.3 186 25.5 83
CIN2 18.6 238 28.0 95 17.9 110 10.1 33
CIN3 17.7 226 15.9 54 22.8 140 9.8 32
AIS 1.5 19 1.5 5 1.8 11 0.9 3
Cervical cancer 1.6 20 0.9 3 1.3 8 2.8 9b
No cervical sample 1.4 18 1.5 5 1.3 8 1.5 5
LLETZ in baseline 37.2 476 24.2 82 43.8 269 38.3 125
Abbreviations: ASC-US: atypical squamous cells of undetermined signiﬁcance; LSIL: low
grade squamous intraepithelial lesion; ASC-H: atypical squamous cells cannot exclude
HSIL; HSIL: high grade squamous intraepithelial lesion; AGC-NOS: atypical glandular
cells not otherwise speciﬁed; AGC-FN: atypical glandular cells favor neoplasia; NILM: neg-
ative for intraepithelial lesion ormalignancy; CIN2: cervical intraepithelial neoplasia grade
2; CIN3: cervical intraepithelial neoplasia grade 3; AIS: adenocarcinoma in situ; LLETZ:
large loop excision of the transformation zone.
a Repeated low-grade cytological abnormality (ASC-US, LSIL, AGC-NOS) in also another
smear six months to two years prior to colposcopy.
b In addition to nine cervical cancers seven endometrial carcinomas were diagnosed in
women ≥45.157) of HSIL+ in women b30, 36.8% (99/269) in women 30–44.9 (RR
1.16, 95% CI 0.88–1.52), and 54.6% (42/77) in women ≥45 (RR 1.71,
95% CI 1.26–2.33). A similar increase with age was seen in the propor-
tion of HSIL+ associatedwith non-vaccine hrHPV types. The proportion
of HPV negative HSIL+ cases increasedwith advancing age, reaching up
to 6.5% in women ≥45 with RR 5.10 (95% CI 1.01–25.68) compared to
women b30 (Table 3). When assuming total cross-protective efﬁcacy
for the bivalent vaccine, in HSIL+ nearly 90% of cases were attributed
to hrHPV types covered by or implicated in bivalent vaccine cross-
protection (HPV16/18/31/33/35/45/52) or coverage of the 9-valent vac-
cine (HPV16/18/31/33/45/52/58) (Table A.2).
CIN3+ was associated with HPV16/18 in 64.2% (154/240) with de-
creasing proportions along increasing age groups as with HSIL+
(Table 3). Other hrHPV types than HPV16/18 accounted for 19.3% (11/
57) of CIN3+ in women b30 and 44.7% (17/38) in women ≥45. For
women ≥45 the risk ratios of having HPV16/18+ CIN3+ was 0.61
(95% CI 0.43–0.88) compared to women under 30. In the 25 AIS+
cases, 72.0% (18/25) were positive for HPV16/18+ and 20.0% (5/25)
were positive for other hrHPV types. All cases of AIS+ in the b30 age
group (5/5) were associated with HPV16/18 whereas in women ≥45
only 33% (2/6). No cases of AIS+ were associated with non-vaccine
targeted hrHPV's (HPV35/39/51/56/59/66/68).
4. Discussion
In this population-based cohort of unvaccinated women referred to
colposcopy for abnormal cytology we found distinct age-speciﬁc pat-
terns of hrHPV type distribution in high-grade cervical disease. The pro-
portions of HSIL+ attributable to HPV16/18 decreased with increasing
age from 64.3% in women under 30 years of age to only 35.1% in
women 45 years or above with the group's median age being only
51.4 years. Conversely, other hrHPV types than HPV16/18 were more
common in HSIL+ in the oldest age group. Furthermore, approximately
10% of HSIL+ cases in the oldest age group were hrHPV negative.
Previous studies have found comparable age-speciﬁc patterns of de-
creasing HPV16/18 positivity with increasing age in invasive cancer and
to a lesser extent in HSIL [25–28]. Our study is to date the largest
population-based study on histopathological HSIL to conﬁrm this age-
speciﬁc type distribution. The reasons for the observed polarisation of
hrHPV types by age remains unclear, but a longer latency to high-
grade disease with other types than HPV16/18 has been suggested, as
well as the reactivation of latent infections after immune senescence
[25,36]. A birth cohort effect, i.e. women born in a certain calendar
time-period having been exposed to different hrHPV types and
screened differently, might also play a role. In Finland the overall cover-
age of organised and opportunistic screening smears (at least one in ﬁve
years) has, however, been over 90% for decades [37]. However, accord-
ing to studies on sexual behavior patterns in industrialized countries
HPV exposures (new sexual partners) are becoming more common in
middle-aged women [38].
HPV16 and 18 antibody levels have been found to be signiﬁcantly
lower for the quadrivalent vaccine compared to the bivalent vaccine
after up to 12 years of follow-up [39]. It is not yet established how
long beyond a decade vaccine immune response lasts, or moreover,
how permanent the moderate to high cross-protection is. When com-
paring the hrHPV type distribution assuming total cross-protective efﬁ-
cacy for the bivalent vaccine there were no major differences between
the bivalent and 9-valent vaccine-covered HPV types in any histopath-
ological categories by age. However, in light of the conﬁrmed age-
speciﬁc polarisation of hrHPV type distribution, the incidence of HSIL
+might not be reduced to the same extent over time following prophy-
lactic vaccination especially if it relies on cross-protection [12,13,20,21].
These data cannot conﬁrm when the older women have acquired the
HPV infections and thus how prophylactic HPV vaccination in adoles-
cence would have altered this. Moreover, larger proportions of high-
grade disease were associated with hrHPV types not targeted by the
Table 2
HPV types of 1279 women by cervical histopathological ﬁndings in age strata.
All b30 30–44.9 ≥45
bHSIL
n = 776
HSIL+
n = 503
bHSIL
n = 182
HSIL+
n = 157
bHSIL
n = 345
HSIL+
n = 269
bHSIL
n = 249
HSIL+
n = 77
Number of HPV types % (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
HPV negative 26.3 (204) 3.4 (17) 17.0 (31) 1.3 (2) 21.5 (74) 3.7 (10) 39.8 (99) 6.5 (5)
Single type 49.0 (380) 67.2 (338) 48.9 (89) 59.2 (93) 53.6 (185) 70.6 (190) 42.6 (106) 71.4 (55)
2 types 17.9 (139) 22.3 (112) 24.2 (44) 26.8 (42) 18.6 (64) 20.8 (56) 12.4 (31) 18.2(14)
≥3 types 6.8 (53) 7.2 (36) 9.9 (18) 12.7 (20) 6.4 (22) 4.8 (13) 5.2 (13) 3.9 (3)
HPV typea
HPV16 13.5 (105) 51.1 (257) 20.9 (38) 59.2 (93) 13.6 (47) 53.2 (143) 8.0 (20) 27.3 (21)
HPV18 5.0 (39) 7.0 (35) 7.1 (13) 7.0 (11) 4.9 (17) 6.7 (18) 3.6 (9) 7.8 (6)
HPV31 6.8 (53) 14.5 (73) 9.9 (18) 14.0 (22) 7.0 (24) 16.4 (44) 4.4 (11) 9.1 (7)
HPV33 2.1 (16) 6.8 (34) 3.3 (6) 8.3 (13) 1.7 (6) 6.0 (16) 1.6 (4) 6.5 (5)
HPV45 4.5 (35) 4.4 (22) 5.0 (9) 3.8 (6) 6.7 (23) 3.7 (10) 1.2 (3) 7.8 (6)
HPV52 5.2 (40) 11.5 (58) 7.1 (13) 10.8 (17) 4.6 (16) 11.5 (31) 4.4 (11) 13.0 (10)
HPV58 2.7 (21) 3.6 (18) 1.1 (2) 3.8 (6) 3.8 (13) 2.6 (7) 2.4 (6) 6.5 (5)
HPV groups
HPV16/18+ 18.0 (140) 56.7 (285) 26.4 (48) 64.3 (101) 18.3 (63) 58.4 (157) 11.7 (29) 35.1 (27)
Other hrHPV+b 38.1 (296) 38.0 (191) 39.6 (72) 31.9 (50) 42.9 (148) 36.8 (99) 30.5 (76) 54.6 (42)
Non-vaccine hrHPV+c 20.6 (160) 7.0 (35) 21.4 (39) 5.1 (8) 22.3 (77) 5.6 (15) 17.7 (44) 15.6 (12)
Only low-risk HPV+d 17.5 (136) 2.0 (10) 17.0 (31) 2.6 (4) 17.4 (60) 1.1 (3) 18.1 (45) 3.9 (3)
Abbreviations: bHSIL: normal histopathological ﬁndings or cervical intraepithelial neoplasia grade 1 (CIN1)/histopathological low-grade squamous intraepithelial lesion (LSIL); HSIL+:
histopathological CIN2, CIN3, adenocarcinoma in situ (AIS), squamous cell carcinoma, adenocarcinoma.
a Irrespective of multiple infections.
b HPV31/33/35/39/45/51/52/56/58/59/66/68-positive.
c HPV35/39/51/56/59/66/68-positive.
d HPV6/11/30/40/42/43/53/61/67/69/70/73/74/81/83/86/87/89/90/91-positive.
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cases of CIN3+ in women b30 and 5/38 (13.2%) in women ≥45).
When assessing and modelling the efﬁcacy of vaccination with dif-
ferent screening and reﬂex-testing strategies, the distinct age-speciﬁc
hrHPV type distribution should not be overlooked. HPV16/18Fig. 1. HPV type distribution in 503 high gradgenotyping has been considered beneﬁcial as an adjunctive triage test,
regardless of age [33,40]. Our ﬁndings should be carefully considered
when applying HPV16/18 genotyping as a triage test — only approxi-
mately a third of HSIL+ in the older women was attributed to these
types. Furthermore, in a large retrospective study approximately 20%e cervical lesions in different age strata.
Table 3
Histopathological CIN2, CIN3+, and HSIL+ according to HPV groups in age strata and risk ratios (RR) for HPV group positive high-grade histology with women b30 set as the referent
group.
HPV16/18+
n = 425
Other hrHPV+
n = 487
Non-vaccine hrHPV+
n = 195
Only low risk HPV+
n = 146
HPV negative
n = 221
n (%) RR (95% CI) n (%) RR (95% CI) n (%) RR (95% CI) n (%) RR (95% CI) n (%) RR (95% CI)
HSIL+ b30
N = 157
101 (64.3) Ref 50 (31.9) Ref 8 (5.1) Ref 4 (2.6) Ref 2 (1.3) Ref
HSIL+ 30–44.9
N = 269
157 (58.4) 0.91 (0.78–1.06) 99 (36.8) 1.16 (0.88–1.52) 15 (5.6) 1.09 (0.47–2.52) 3 (1.1) 0.44 (0.10–1.93) 10 (3.7) 2.9 (0.65–13.15)
HSIL+ ≥45
N = 77
27 (35.1) 0.55 (0.39–0.75) 42 (54.6) 1.71 (1.26–2.33) 12 (15.6) 3.06 (1.30–7.17) 3 (3.9) 1.53 (0.35–6.66) 5 (6.5) 5.10 (1.01–25.68)
HSIL+ total
N = 503
285 (56.7) 191 (38.0) 35 (7.0) 10 (2.0) 17 (3.4)
CIN2 b30
N = 95
52 (54.7) Ref 39 (41.1) Ref 8 (8.4) Ref 3 (3.2) Ref 1 (1.1) Ref
CIN2 30–44.9
N = 110
54 (49.1) 0.90 (0.69–1.17) 50 (45.5) 1.11 (0.81–1.52) 9 (8.2) 0.97 (0.39–2.42) 3 (2.7) 0.86 (0.18–4.18) 3 (2.7) 2.59 (0.27–24.49)
CIN2 ≥45
N = 33
7 (21.2) 0.39 (0.20–0.77) 22 (66.7) 1.62 (1.15–2.28) 7 (21.2) 2.52 (0.99–6.41) 1 (3.0) 0.96 (0.10–8-91 3 (9.1) 8.63 (0.93–80.17)
CIN2 total
N = 238
113 (47.5) 111 (46.6) 24 (10.1) 7 (2.9) 7 (2.9)
CIN3+ b30
N = 57
44 (77.2) Ref 11 (19.3) Ref 0 (0.0) Ref 1 (1.8) Ref 1 (1.8) Ref
CIN3+ 30–44.9
N = 145
92 (63.5) 0.82 (0.68–0.99) 47 (32.4) 1.68 (0.94–3.00) 6 (4.1) NA 0 (0.0) NA 6 (4.1) 2.36 (0.29–19.16)
CIN3+ ≥45
N = 38
18 (47.4) 0.61 (0.43–0.88) 17 (44.7) 2.32 (1.23–4.39) 5 (13.2) NA 2 (5.3) NA 1 (2.6) 1.50 (0.10–23.26)
CIN3+ total
N = 240
154 (64.2) 75 (31.3) 11 (4.6) 3 (1.3) 8 (3.3)
Deﬁnitions: CIN2: cervical intraepithelial neoplasia grade 2; CIN3+: cervical intraepithelial neoplasia grade 3 and squamous cell carcinoma; AIS+: adenocarcinoma in situ and adenocar-
cinoma; HSIL+: CIN2, CIN3, AIS, squamous cell carcinoma, adenocarcinoma; other hrHPV+: HPV31/33/35/39/45/51/52/56/58/59/66/68-positive; non-vaccine hrHPV+: HPV35/39/51/
56/59/66/68-positive; only low-risk HPV+: HPV6/11/30/40/42/43/53/61/67/69/70/73/74/81/83/86/87/89/90/91-positive; Ref: reference; NA: not applicable.
358 K. Aro et al. / Gynecologic Oncology 154 (2019) 354–359of invasive cervical cancers were HPV negative [41], while 10% HSIL+
lesions in the oldest age group were also hrHPV negative here. These
ﬁndings should be taken into consideration when shifting to HPV-
based screening with the majority of screening-age population still
being unvaccinated. Overall approximately 95% of HSIL lesions here
were positive for hrHPV types included in most HPV tests approved
for screening: up to 96% in women under 30 and 90% in women over
45. Detection of the hrHPV negative lesions would perhaps warrant
co-testing with cytology when screening older women who previously
have not attended HPV-based screening. This type of strategy has been
implemented in Sweden where women approximately 41 years of age
are co-tested [42]. However, in women under the age of 30 nearly 90%
of CIN3+and all cases AIS+were associatedwithHPV16/18 in compar-
ison to only approximately half of CIN2 cases and a fourth of bHSIL cases.
HPV16/18 positivity in this age group can be considered to be strongly
associated with true high-grade disease. Screening for all hrHPV types
in young women would not, in light of these data, result in detection
of signiﬁcantly more HSIL+, but rather reduce the positive predictive
value of the HPV screening test. Stratiﬁcation of screened HPV types ac-
cording to age could be hence considered.
Strengths of our study are generalisability ofﬁndingswith the cohort
deriving from an unselected population of a single referral center serv-
ing a large population base with likely high prior attendance of
cytology-based cervical cancer screening. Our data should accurately re-
ﬂect the current hrHPV type distribution in clinically relevant disease
omitting transient infections. HPV status was determined using high-
quality HPV genotyping in an international HPV reference laboratory,
with a very low number of unsuccessful samples. Weaknesses of the
study include the small number of cases glandular disease and invasive
cancers. The numbers of infections with individual HPV types were also
low, excluding HPV16. Our study assessed real-life age-speciﬁc HPV
type distribution in women requiring colposcopy, not a cross-section
of a screening population. Due to this, we were able to include morecases of HSIL+ than studies in screening populations, but the data
therefore cannot directly be used to estimate HPV burden in the
whole population.
In conclusion, our results showed that HPV type distribution in high-
grade cervical lesions is distinctly polarised according to age in a highly
screened population with HPV16/18 attributed disease most prevalent
in younger women. In women over 45, only a third of the HSIL+ ﬁnd-
ings were attributable to HPV16/18, while other hrHPV types and
hrHPV negativity were more prevalent. The performance of current
HPV-based screening is hence age-dependent and could bemodiﬁed ac-
cording to age to achieve better predictive values. Furthermore, when
the majority of the screening-aged population is still unvaccinated
hrHPV test only might not be optimal screening strategy, especially
among older women with low prior adherence to screening.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2019.05.024.
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